NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Last trade$15.18
Day change-$0.23 (-1.49%)
Day range$14.98 – $15.73
Volume524,433
Market cap$1.99B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.99B
Price / earnings
—
Price / book
2.49×
Price / sales
2.53×
EV / sales
2.84×
EV / EBITDA
135.74×
Profitability
Earnings per share
-$0.25
Return on assets
-2.35%
Return on equity
-4.03%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.48×
Current ratio
3.53×
Quick ratio
3.31×
Cash ratio
1.2×
Cash flow
Price / cash flow
465.86×
Price / free cash flow
—
Free cash flow
-$28.58M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NEO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$209.25M
$201.66M
$186.67M
$190.17M
$187.8M
$181.33M
$168.04M
$172M
Cost of revenue
$112.67M
$109.78M
$105.81M
$106.83M
$107.35M
$104.07M
$94.79M
$94.74M
Gross profit
$96.59M
$91.88M
$80.86M
$83.34M
$80.45M
$77.26M
$73.25M
$77.26M
Selling, general and administrative
$94.67M
$90.89M
$89.57M
$86.95M
$91.68M
$95.82M
$90.89M
$85.98M
Research and development
$9.86M
$10.76M
$9.53M
$9.18M
$8.69M
$9.02M
$10.18M
$7.97M
Total operating expenses
$104.53M
$101.65M
$99.11M
$96.76M
$107.46M
$124.89M
$101.07M
$95.66M
Operating income
-$7.94M
-$9.77M
-$18.24M
-$13.41M
-$27.01M
-$47.63M
-$27.83M
-$18.4M
Interest expense
-$1.27M
-$781K
-$598K
-$599K
-$603K
-$933K
-$1.62M
-$1.62M
Income before taxes
-$8.02M
$1.83M
-$17.58M
-$12.41M
-$26.39M
-$45.82M
-$25.66M
-$16.13M
Income taxes
-$475K
-$412K
-$472K
-$2.53M
$740K
-$724K
$266K
-$804K
Net income
-$7.55M
$2.24M
-$17.11M
-$9.88M
-$27.13M
-$45.09M
-$25.92M
-$15.32M
Net income attributable to common shareholders
-$7.55M
$2.24M
-$17.11M
-$9.88M
-$27.13M
-$45.09M
-$25.92M
-$15.32M
EBITDA
$8.25M
$6.44M
-$1.83M
$3.61M
-$3.49M
-$10.32M
-$10.1M
$1.49M
Basic earnings per share
-$0.06
$0.02
-$0.13
-$0.08
-$0.21
-$0.35
-$0.20
-$0.12
Diluted earnings per share
-$0.06
$0.02
-$0.13
-$0.08
-$0.21
-$0.35
-$0.20
-$0.12
Recent news
Company coverage with links to the original publishers.
NeoGenomics reported Q3 2026 earnings of $0.07 per share, beating consensus estimates of $0.06, with revenues of $209.25 million slightly exceeding expectations. The company has outperformed the market by 46.9% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. ADC Therapeutics is expected to report a quarterly loss of $0.21 per share.
The State Street SPDR S&P Health Care Services ETF (XHS) is a passively managed healthcare services sector ETF with low costs (0.35% expense ratio) and solid year-to-date performance of 27.29%. The fund holds about 62 healthcare companies with a medium risk profile (beta of 0.93) and carries a Zacks ETF Rank of 3 (Hold), making it a reasonable option for investors seeking diversified healthcare sector exposure.
BCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.
Insider activity increased in stocks such as Hudson Pacific Properties, NeoGenomics, and Carvana, signaling opportunities for traders and investors. The article examines who is buying, the forces driving their underlying markets, and the potential upside.
Three stocks across multiple sectors may draw the attention of investors looking for a momentum play - Oddity Tech Ltd, NeoGenomics Inc, and Comfort Systems USA Inc. These companies have seen significant share price improvements and positive analyst ratings, suggesting potential for continued upside.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.